Effects and cases of Ocriplasmin in treating epiretinal membrane

Ocriplasmin (Ocriplasmin) has also shown positive clinical value in the treatment of epiretinal membrane (ERM). The epiretinal membrane is a fibrous membrane formed on the surface of the retina. As the disease progresses, it can lead to traction on the fovea and distortion of vision, seriously affecting the patient's vision and quality of life. The traditional treatment method is mostly vitrectomy, but the surgery is invasive and carries the risk of complications, such as retinal detachment, macular holes, and accelerated cataract formation after surgery. Oak plasmin softens the interface between the membrane and the vitreous body through enzymatic action, so that the vitreous body can be naturally peeled off under physiological conditions, thereby reducing the traction on the epimacular membrane.

Clinical cases show that after some patients with mild to moderate macular epiretinal membrane were injected with Oak plasmin, the macular traction was relieved, the foveal morphology was improved, and the visual acuity and visual distortion symptoms were also improved. For example, in some patients, within a few weeks after a single injection, the separation of the interface between the epiretinal membrane and the vitreous body and the restoration of the retinal layer structure can be observed through OCT images. While efficacy varies among individuals, Oakplasmin provides an important option for patients who cannot tolerate surgery or who wish to delay surgery.

It should be pointed out that Oakplasmin may have limited effect on thick or long-standing macular epiretinal membrane, and some patients still require surgical intervention after drug treatment. In terms of drug safety, most patients tolerate it well, but temporary vision fluctuations, increased floaters in the eye, or changes in intraocular pressure may occur. Overall, Oakplasmin provides a non-surgical, minimally invasive and reproducible intervention in the treatment of macular epiretinal membrane, which is especially suitable for early or mild cases and provides a complementary treatment strategy for clinical use.

Reference materials:https://www.drugs.com/cdi/ocriplasmin.html